Cantargia AB BTA (CANTA.BTA)

Overview

Cantargia AB (publ), based in Lund, Sweden, is a pioneering biotechnology firm focused on the research and development of innovative antibody-based therapies for life-threatening diseases. With its establishment in 2009, the company has dedicated itself to creating solutions that target specific elements of diseases, aiming to improve survival and quality of life for patients worldwide. Through collaboration agreements with industry leaders, such as Patheon Biologics B.V., BioWa Inc., Allucent, the Pancreatic Cancer Action Network, and the Spanish breast cancer group GEICAM, Cantargia has been able to advance its development programs significantly, leveraging expertise and resources to push its products closer to commercialization.

Products and Services

• CAN04 (Nadunolimab)

CAN04, known also as Nadunolimab, is an innovative antibody targeting the interleukin-1 receptor accessory protein (IL1RAP). This product is at the forefront of Cantargia's pipeline, currently undergoing Phase II clinical trials for the treatment of pancreatic cancer and non-small cell lung cancer. Additionally, it is in a Phase Ib/II trial stage for triple-negative breast cancer. The development of Nadunolimab represents a promising step forward in the targeted treatment of these challenging cancer types, offering potential improvements in patient outcomes.

• CAN10

A pioneering antibody that zeroes in on IL1RAP, CAN10 is in the preclinical phase, designed for the treatment of autoimmune and inflammatory diseases such as systemic sclerosis and myocarditis. The development of CAN10 illustrates Cantargia's commitment to expanding the application of its IL1RAP-targeted therapy beyond oncology, addressing the unmet needs of patients suffering from severe autoimmune and inflammatory conditions.

• CANxx

The CANxx project represents Cantargia's IL1RAP-based antibody platform, which underpins both CAN04 and CAN10, among others. This platform serves as the foundation for the company's ongoing research and development efforts, signifying its broader strategy to exploit IL1RAP as a therapeutic target in various diseases. The diversification and expansion of its pipeline through the CANxx platform manifest Cantargia's commitment to innovative science and its potential to deliver novel therapies for life-threatening conditions.